KR20110086473A - Composition for preventing or treatment of coronavirus infection and composition for inhibiting the activy of 3c-like protease comprising ecklonia cava - Google Patents

Abstract

PURPOSE: A composition containing Ecklonia cava extract or fraction of the extract for preventing or treating coronaviral infection is provided to suppress 3CL protease activity. CONSTITUTION: A composition for preventing or treating coronaviral infection contains Ecklonia cava extract or fraction of the extract as an active ingredient. The extract is isolated using water, alcohol of C1-C4, or mixture solvent thereof. The fraction is a hexane fraction, ethyl acetate fraction, or water fraction. The composition is a pharmaceutical or food composition. The pharmaceutical composition is manufactured in the form of tablet, pill, powder, granule, capsule, suspension, emulsion, syrup, non-aqueous solvent, suspension, or suppository. A composition for suppressing 3CL protease activity contains the extract or fraction of the extract as an active ingredient.

Description

Composition for preventing or treatment of coronavirus infection and composition for inhibiting the activy of 3C-like protease comprising ecklonia cava}

The present invention relates to compositions for the prevention and treatment of coronavirus infection and compositions for inhibiting 3CL protease activity, including Ecklonia cava extract or fractions thereof.

Coronavirus was first discovered in chickens in 1937 and then in humans in 1965 through animals such as dogs, pigs and birds. It is named after the solar eclipse when the solar eclipse is covered by the moon.

Until now, the corona virus has been recognized as a pathogen that is hardly infected by humans and mainly infects animals such as dogs, pigs, and cattle. Even when infected with humans, one of several viruses that cause respiratory symptoms may cause a simple cold or a bowel disease such as diarrhea in children. However, as the causative agent of Severe Acute Respiratory Syndrome (SARS: SARS), which occurred for the first time in mid-March 2003 and caused more than 100 deaths and 3,000 patients worldwide, it is becoming increasingly known as the new (variant) coronavirus. I started to receive.

Coronaviruses are known to cause pneumonia and enteritis mainly in humans and animals, and sometimes to cause nervous system infections and hepatitis. Coronavirus is a positive sense RNA virus of about 100-120 nm in size, with a spherical outer membrane belonging to the family Coronaviridae (Master, 2006). Coronavirus consists of five structural proteins (Lai), the outermost spike protein (S), hemagglutinin-esterase (HE) protein, transmembrane (M) protein, small membrane (E) protein, and nucleocapsid (N) protein. and Homes, 2001. Fields Virology). Among these, the spike protein acts as a ligand that binds to cellular receptors, and is known as the most mutated protein as a protein that induces fusion between the host cell and the virus.

Coronaviruses are largely divided into three serotypes. The first serotype is a causative agent of infectious enteritis in pigs, and this disease is also occurring in Korea, and it is important in domestic pig farming because it causes an incidence of 100% of young piglets and mortality of 70% or more. The second serotype is bovine coronavirus infection, which is important in livestock. The third serotype is chicken infectious bronchitis, which causes respiratory, urinary and spawning disorders in chickens. Bovine coronavirus, unlike other serotype viruses, has a second spike in the outer membrane of the virus, hemaggulitin, which is distinguished morphologically, serologically and genetically. In particular, the second serotype is very important as a serotype belonging to SARS coronavirus, which occurred in 2002 in China and caused fear around the world. According to the WHO statistics, SARS coronavirus has reported a total of 8,500 infections, of which 800 have died. Recently, it has been found that SARS coronavirus has been transmitted to humans from bats, and coronavirus infection due to heterogeneous transmission has become a big problem.

Coronavirus control targets can be divided into cell invasion inhibition, cytokine (IFN), RNA replication inhibition and viral protease inhibition. Coronavirus control targets that are currently being actively studied include the viral protease 3C-like protease (3CL ^pro or 3CL protease) and papain like protease (PL ^pro ). Research is being actively conducted. Valinomycin (IC ₅₀ = 0.85 μM), reserpine (IC ₅₀ = 3.4 μM) and TL3 are currently being developed as new drugs or in clinical stages.

In line with these studies, it was found that the group of terpenoid and lignoid compounds isolated from biomaterials of cypress, cypress and cedar had strong inhibitory activity of the target protease Wen CC ( J. Med . Chem . 2007), TF3 (theaflavin-3,3'-digallate) isolated from green tea and black tea is known as a protease inhibitor (Chen, C.-N. et al., ECAM , 2005). Except for the development of coronavirus target proteases from a few biomaterials, all other inhibitors have been reported as synthetic peptides. In addition, the representative material having a cytopathic (CPE) inhibitory effect of the virus is based on its activity in glycyrrhizin and the glycoside compound, which is isolated from the medicinal plant Licorice , Studies are actively underway (Hoever et al., J. Med . Chem . 2005, Cinatl et al., Lancet , 2003).

Antivirals developed to date have severe side effects, so much care is required in their applications. In addition, the development of a vaccine has a problem that the effect is low if the virus of the virus and the type of the epidemic does not match, there is an increasing need for the development of a new coronavirus agent with excellent infection suppression effect and excellent stability. In addition, the 3CL protease of SARS-Coronavirus is less mutated and its structure is revealed, so it can be applied not only to SARS-Coronavirus but also to bovine coronaviruses of the same serotype and swine coronaviruses of other serotypes. .

Therefore, the present inventors selected 3CL protease and various targets that play an important role in the transcription and replication of coronavirus, and the Ecklonia cava extract and fractions capable of inhibiting the virus have the inhibitory activity against 3CL protease, the virus killing effect against virus and cells The present invention was completed by confirming that there is an inhibitory effect on degeneration.

It is an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of a coronavirus infection and a method of treatment using the same.

Another object of the present invention is to provide a food composition for the prevention or treatment of coronavirus infection.

Another object of the present invention is to provide a quasi-drug composition for the prevention or treatment of coronavirus infection.

Still another object of the present invention is to provide a composition for inhibiting 3CL protease activity and a method of inhibiting the same, which can be used to treat 3CL protease activity and to treat diseases related thereto.

In one aspect of the present invention for achieving the above object, there is provided a composition for the prevention or treatment of corona virus infection comprising an Ecklonia cava extract or a fraction thereof as an active ingredient.

According to another aspect of the present invention, there is provided a composition for inhibiting 3CL protease activity comprising an Ecklonia cava extract or a fraction thereof as an active ingredient.

According to another aspect of the invention, there is provided a method of inhibiting the activity of a 3CL protease comprising contacting the composition with a sample comprising a 3CL protease.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for preventing or treating coronavirus infection comprising an Ecklonia cava extract or a fraction thereof as an active ingredient.

The composition of the present invention can be used for the prevention or treatment of coronavirus infection because it blocks the spread of coronavirus to other cells in the respiratory tract by inhibiting the activity of the 3CL protease, which is present on the surface of the corona virus and plays an essential function in viral replication. have.

As used herein, the term "prevention" means any action that inhibits or delays the development of a coronavirus infection by administration of a composition.

As used herein, the term "treatment" means any action that improves or advantageously changes the symptoms caused by coronavirus infection by administration of the composition.

The corona virus may be SARS, Porcine, or Bovine corona virus, and preferably, it may be SARS corona virus. In addition, the corona virus can cause diseases of the flu, cold, sore throat, bronchitis, and pneumonia.

Common Eckloniatic ( Ecklonia cava ) is a perennial seaweed of the seaweed ( Alariaceae ), which grows deep in the luncheon. The length is usually 1-2m, the stem is cylindrical, and the root is root shaped.

In the present invention, Ecklonia cava can be used to buy commercially available, or can be used directly collected from Jeju Island.

The method of preparing the extract of Ecklonia cava may be a conventional extraction method in the art, such as ultrasonic extraction, filtration and reflux extraction. Preferably, the dried Ecklonia cava obtained by pulverizing Ecklonia cava from which foreign substances are removed by washing and drying may be an extract extracted with water, an alcohol of C ₁ to C ₄ , or a mixed solvent thereof, and more preferably, C ₁ to C ₄ . It may be an extract extracted with alcohol, most preferably may be an extract extracted with methanol or ethanol. At this time, the extraction solvent is preferably 2 to 20 times the dry weight of the Ecklonia cava. For example, after cutting the Ecklonia cava dry, put it in an extraction container and put a lower alcohol of C ₁ ~ C ₄ or a mixed solvent thereof, preferably methanol or ethanol, and leave it at room temperature for a certain period of time, followed by filtration to obtain an alcohol extract. . At this time, the extraction is preferably left for 1 week at room temperature, after which it may be further subjected to methods such as concentration or lyophilization.

In addition, the dried Ecklonia cava was allowed to stand for 6 hours by connecting hot water at 80 to 90 ° C. to a reflux device, and then filtered to obtain a hot water extract. Thereafter, a method such as concentration or lyophilization may be additionally performed.

Meanwhile, the Ecklonia cava fraction in the present invention can be obtained by fractionation from the Ecklonia cava extract obtained above. More specifically, the Ecklonia cava fraction can be obtained by suspending the Ecklonia cava extract in water and then fractionating it with hexane and ethyl acetate, respectively, to obtain a hexane fraction, an ethyl acetate fraction and a water fraction.

Meanwhile, the composition for preventing or treating coronavirus infection of the present invention may be a pharmaceutical composition.

When the composition of the present invention is a pharmaceutical composition, the composition may include a pharmaceutically acceptable carrier. The composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose ( lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have one formulation.

The composition of the present invention is administered in a pharmaceutically effective amount.

As used herein, the term "pharmaceutically effective amount" refers to an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the individual type and severity, age, sex, type of virus infected. , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the drug used concurrently, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.

The composition of the present invention can be used alone or in combination with methods using surgery, hormonal therapy, drug therapy and biological response modifiers for the prevention or treatment of coronavirus infection.

On the other hand, the present invention provides a method for treating a coronavirus infection disease comprising administering the composition for the prevention or treatment of coronavirus infection in a pharmaceutically effective amount to a subject having the possibility of the invention or onset of coronavirus infection. . The corona virus may be SARS, Porcine, or Bovine corona virus, and preferably the SARS corona virus. In addition, the corona virus infection disease may be flu, cold, sore throat, bronchitis, and pneumonia.

As used herein, the term "individual" means all animals, including humans already infected with or capable of being infected with a coronavirus, and by effectively administering to a subject a composition comprising an extract or fraction of the present invention, thereby effectively preventing and treating the disease. Can be. For example, the compositions of the present invention can treat humans infected with various coronavirus subtypes or variants of human coronavirus. In addition, the compositions of the present invention can treat humans infected with various coronavirus subtypes or variants of coronavirus. It is also possible to treat pigs or cattle infected with various coronavirus subtypes or variants of coronaviruses. The composition of the present invention can be administered in parallel with a therapeutic agent for existing coronavirus infection disease.

The route of administration of the composition may be administered via any general route as long as it can reach the desired tissue. The composition of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, pulmonary administration, rectal administration. The composition may also be administered by any device in which the active agent may migrate to the target cell.

In addition, the present invention provides a food composition for the prevention or treatment of corona virus infection comprising an Ecklonia cava extract or a fraction thereof as an active ingredient.

That is, the Ecklonia cava extract of the present invention or a fraction thereof may be added to a food composition for preventing or treating corona virus infection. When the Ecklonia cava extract of the present invention or a fraction thereof is used as a food additive, the extract or fraction may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient can be determined suitably according to the purpose of use (prevention, health or therapeutic treatment). In general, in the manufacture of food or beverages, the composition of the present invention is added in an amount of 0.01 to 10% by weight, preferably 0.05 to 1% by weight based on the raw materials. However, in the case of prolonged ingestion for health and hygiene purposes or for health control purposes, the amount may be used below the above range.

There is no particular limitation on the kind of food. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention. These components can be used independently or in combination.

In addition, the present invention provides a quasi-drug composition for the prevention or treatment of corona virus infection comprising an Ecklonia cava extract or a fraction thereof as an active ingredient.

That is, the composition of the present invention may be added to the quasi-drug composition for the purpose of preventing or treating coronavirus infection. When the Ecklonia cava extract of the present invention or a fraction thereof is used as an quasi-drug additive, the extract or fraction may be added as it is or used together with other quasi-drug components, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).

Preferably, the quasi-drug composition may be an antiseptic agent, a shower foam, a gagreen, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.

The present invention also provides a composition for inhibiting 3CL protease activity comprising an Ecklonia cava extract or a fraction thereof as an active ingredient.

At this time, the composition for inhibiting the 3CL protease activity may be used for the prevention or treatment of SARS, Porcine, or Bovine coronavirus, preferably for the prevention or treatment of SARS coronavirus. Can be used.

The SARS, Porcine, or Bovine corona virus can cause diseases of the flu, cold, sore throat, bronchitis, and pneumonia.

The present invention also provides a method of inhibiting the activity of the 3CL protease comprising the step of contacting the composition for inhibiting the 3CL protease activity with a sample containing the 3CL protease. At this time, the contact is made in a conventional manner, the sample containing the 3CL protease is a living organism, tissue or cell culture, biological material samples (blood, serum, urine, cerebrospinal fluid, tears, sputum, saliva, tissue samples, etc.) This may include organisms that produce 3CL proteases, usually pathogenic organisms such as viruses. Such samples can be contained in any medium containing water and an organic solvent / water mixture.

In addition, the activity of the 3CL protease after administration of the composition of the present invention can be observed by any method including a direct or indirect method of diagnosing 3CL protease activity. Either quantitative, qualitative or semi-quantitative methods of diagnosing the activity of the 3CL protease may be used, and any other method may be applied, such as observing the physiological properties of living organisms.

Compositions comprising Ecklonia cava extracts or fractions thereof according to the present invention exhibit the effect of inhibiting the activity of the 3CL protease, and at the same time exhibits the effect of inhibiting virucidal and cytopathic effects on various coronaviruses, which is useful for the prevention or treatment of coronavirus infection. Can be used.

Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples. However, the following examples are merely to illustrate the present invention is not limited to the contents of the present invention.

Example  One : Ecklonia  Preparation of Extract

The Ecklonia cava used in the present invention is generally easily collected in nature, and was used by pulverizing in powder form in order to efficiently obtain the extract of the present invention.

20 L of 95% ethanol (EtOH) was added to 2 kg of Ecklonia cava, and allowed to stand at room temperature for 7 days, filtered through a filter paper, and concentrated to give an ethanol extract (182 g) of Ecklonia cava.

Example  2 : Ecklonia  From extract Fraction  And purification of compounds

2 L of water was added to 182 g of the ethanol extract of Ecklonia cava obtained in Example 1 and suspended. This was put in a separatory funnel to obtain hexane soluble extract (48 g), ethyl acetate soluble extract (90 g) and water soluble extract (20 g).

90 g of the ethyl acetate soluble extract obtained above was subjected to silica gel column chromatography [silica gel 700 g, 70 to 230 mesh] using chloroform, methanol, and a mixed solvent thereof (30: 1 to 1: 1) as a mobile phase. And separated into 12 fractions (Fr. 1-12). The second of these fractions (Fr. 2, 1.2 g) Using a mixed solvent of hexane: ethyl acetate as a mobile phase, silica gel column chromatography (100 g, 230-400 mesh) was carried out again under TLC developing solvent hexane: ethyl acetate (1: 2) to obtain three fractions (Fr. 2). -1 to 2-3). Sephadex (LH-20) column chromatography with methanol was performed on the first fraction (Fr. 2-1, 230 mg) to obtain pure Compound 1 (21 mg). Pure compound 2 (21 mg) using reverse phase chromatography (RP-18) using a methanol: water mixed solvent (30/70, v / v) for the second fraction (Fr. 2-2, 330 mg) Obtained. In addition, the third fraction (Fr. 2-3, 560 mg) was subjected to silica gel column chromatography (50 g, 230 ~) under conditions of TLC developing solvent hexane: ethyl acetate (1: 2) using a mixed solvent of hexane: ethyl acetate as a mobile phase. 400 mesh) and pure compound 3 (30 mg) was obtained using reverse phase chromatography (RP-18) using a methanol: water mixed solvent (30/70, v / v).

Example  3: structural analysis of the obtained compound

Molecular weight and molecular formula of the compounds obtained in Example 2 were analyzed by ¹ N NMR, ¹³ C NMR and 2D NMR spectroscopy data, melting point and infrared spectroscopy through nuclear magnetic resonance (NMR) analysis (Bruker AM 300, 500). IR) data were used to determine the molecular structure.

Experimental Example  One : Ecklonia  Extract and Fraction  3 CL  Protease ( SARS CoV  3 CL  Protease) inhibitory activity measurement

In order to measure the inhibitory activity of the Ecklonia cava extracts and fractions of Examples 1 and 2 on 3CL protease, a recombinant 3CL protease (LifeSensor) of SARS coronavirus was purchased and used. The substrate was used to purchase Dacyl-KTSAVLQSGFKME-Edans for Fluorescence Resonance Energy Transfer (FRET) assay.

Ecklonia cava extracts and fractions of Examples 1 and 2 were dissolved in methanol, added 20 μL each, 50 μL of substrate Dacyl-KTSAVLQSGFKME-Edans (final concentration, 2.5 μM) was added, and 20 mM Bis-Tris buffer (pH 7.5). 80 μL was mixed and reacted for 60 minutes at room temperature by adding 50 μL of the enzyme source 3CL protease (enzyme final concentration, 2.5 μg / mL), excitation at 360/40 nm and 590 / Inhibitory activity of 3CL protease was measured by measuring the emission value at 20 nm.

The measurement results are shown in Table 1 below.

Sample Name 3CL protease inhibition rate (IC ₅₀ , μg / mL) Ethanol Extract of Ecklonia cava 7.5 Hydrothermal Extract of Ecklonia cava 28.0 Hexane fraction of Ecklonia cava 12.3 Ethyl Acetate Fraction of Ecklonia cava 5.3

As shown in Table 1, as a result of measuring the inhibitory activity of the Ecklonia cava extract and fractions according to the present invention on the 3CL protease, 7.5, 28.0, 12.3, in the ethanol extract, hydrothermal extract, hexane, ethyl acetate and water fractions of Ecklonia cava And an IC ₅₀ value of 5.3 μg / mL. Therefore, it was confirmed that Ecklonia cava ethyl acetate fraction had the highest inhibitory activity.

Hereinafter, examples of pharmaceutical preparations or health foods containing Ecklonia cava extract and fractions will be described.

Manufacturing example  1: Preparation of pharmaceutical preparation

1-1. Powder  Produce

Ecklonia cava extract or fractions thereof 2 g

1 g lactose

After mixing the above components, the airtight cloth was filled to prepare a powder.

1-2. Manufacture of tablets

Ecklonia cava extract or its fractions 100 mg

100 mg corn starch

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

1-3. Preparation of Capsules

Ecklonia cava extract or its fractions 100 mg

100 mg corn starch

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

1-4. Preparation of Injection

Ecklonia cava extract or fractions thereof 10 ㎍ / ml

Dilute hydrochloric acid BP until pH 3.5

Injectable sodium chloride BP up to 1 ml

Ecklonia cava extract or fractions thereof were dissolved in an appropriate volume of sodium chloride BP for injection, and the pH of the resulting solution was adjusted to pH 3.5 with dilute hydrochloric acid BP, and the volume was adjusted with sodium chloride BP for injection and thoroughly mixed. The solution was filled into a 5 ml Type I ampoule made of clear glass, encapsulated under an upper grid of air by dissolving the glass, and sterilized by autoclaving at 120 ° C. for at least 15 minutes to prepare an injection solution.

Manufacturing example  2: manufacture of health food

2-1. Preparation of Cooking Seasonings

Ecklonia cava extract or fractions thereof prepared from 0.2 to 10% by weight for health promotion cooking seasoning.

2-2. tomato ketchup  And preparation of sauces

Health promotion tomato ketchup or sauce was prepared by adding 0.2 ~ 1.0% by weight of Ecklonia cava extract or fractions thereof to tomato ketchup or sauce.

2-3. Manufacture of flour food products

Ecklonia cava extract or fractions thereof from 0.1 to 5.0% by weight was added to the flour, using the mixture to prepare bread, cakes, cookies, crackers and noodles to prepare health foods.

2-4. soup  And juicy ( gravies Manufacturing

Ecklonia cava extract or fractions thereof from 0.1 to 1.0% by weight was added to the soup and gravy to prepare health products, health soup and soup.

2-5. ground Beef  ( ground beef)  Produce

10% by weight of Ecklonia cava extract or fractions thereof was added to the ground beef to prepare ground beef for health promotion.

2-6. dairy product ( dairy products Manufacturing

Ecklonia cava extract or fractions thereof from 0.1 to 1.0% by weight was added to the milk, using the milk to prepare a variety of dairy products such as butter and ice cream.

2-7. Solar  Produce

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

Ecklonia cava extract or fractions thereof were concentrated under reduced pressure in a vacuum concentrator and dried by spraying and drying with a hot air dryer to pulverize the dried product to a particle size of 60 mesh to obtain a dry powder.

Cereals, seeds and Ecklonia cava extract or its dried powder prepared in the above ratio was prepared by combining the following ratio.

Cereals (30% brown rice, 15% barley, 20% barley),

Seeds (7% by weight perilla, 8% by weight black beans, 7% by weight black sesame seeds),

Dry powder of Ecklonia cava extract or fractions thereof (1% by weight),

Ganoderma lucidum (0.5% by weight),

Foxglove (0.5 wt%)

2-8. Preparation of Carbonated Drinks

5-10% of sugar, 0.05-0.3% citric acid, 0.005-0.02% caramel, 0.1-1% of vitamin C are mixed, and 79-94% purified water is added to make syrup, and the syrup is 85-98 Sterilizing at 20 ℃ for 180 seconds, mixed with cooling water in a ratio of 1: 4, and then injected with carbon dioxide gas 0.5 ~ 0.82% to prepare a carbonated beverage containing Ecklonia cava extract or a fraction thereof.

2-9. Health drink  Produce

Instant sterilization by homogeneous mixing of subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%) and Ecklonia cava extract or fractions thereof. Healthy drinks were prepared by packaging in small packaging containers such as glass bottles and plastic bottles.

2-10. Preparation of Vegetable Juice

0.5 g of Ecklonia cava extract or a fraction thereof was added to 1,000 ml of tomato or carrot juice to prepare a vegetable juice for health promotion.

2-11. Manufacture of fruit juice

0.1 g of Ecklonia cava extract or a fraction thereof was added to 1,000 ml of apple or grape juice to prepare a fruit juice for health promotion.

Claims (11)

Composition for the prevention or treatment of corona virus infection comprising an Ecklonia cava extract or a fraction thereof as an active ingredient. According to claim 1, wherein the composition is a composition for preventing or treating corona virus infection, characterized in that to inhibit the activity of 3CL protease (3C-like protease). The method of claim 1, wherein the extract is a composition for preventing or treating corona virus infection, characterized in that extracted from water, C ₁ ~ C ₄ alcohol or a mixed solvent thereof. The method of claim 1, wherein the fraction is a hexane fraction, ethyl acetate fraction or water fraction, characterized in that the composition for preventing or treating corona virus infection. The method of claim 1, wherein the corona virus is SARS, Porcine, or Bovine corona virus, characterized in that the composition for the prevention or treatment of corona virus infection. The composition for preventing or treating coronavirus infection according to claim 1, wherein the corona virus causes diseases of flu, cold, sore throat, bronchitis, and pneumonia. The method of claim 1, wherein the composition is a pharmaceutical composition, a food composition or a quasi-drug composition for the prevention or treatment of corona virus infection, characterized in that. The method of claim 7, wherein the pharmaceutical composition is a tablet, pill, powder, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories A composition for preventing or treating coronavirus infection, characterized in that it has any one formulation selected from the group consisting of. The method of claim 7, wherein the food composition is from the group consisting of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes A composition for preventing or treating coronavirus infection, characterized in that any one selected. According to claim 7, wherein the quasi-drug composition is used for the production of any one selected from the group consisting of disinfecting detergent, shower foam, gagreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment and filter filler. A composition for preventing or treating coronavirus infection. Composition for inhibition of 3CL protease activity comprising Ecklonia cava extract or a fraction thereof as an active ingredient.